ORCA
Online Research @ CardiffÂ
Browse by All Cardiff Authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 5.
Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin and Mahajna, Jamal
2021.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K.
Annals of Hematology
100
, pp. 2023-2029.
10.1007/s00277-020-04357-z
|
|
|
|
Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin, Ottmann, Oliver G. and Hantschel, Oliver
2019.
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.
Leukemia
33
, pp. 2319-2323.
10.1038/s41375-019-0468-y
|
|
| Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver and Sewell, Andrew 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3) , pp. 311-322. 10.1182/blood-2017-05-787598 |
|
|
| Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Oliver, Ruthardt, Martin and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46. |
|
| Beissert, Tim, Hundertmark, Alena, Kaburova, Velina, Travaglini, Lorena, Mian, Afsar A., Nervi, Clara and Ruthardt, Martin 2008. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International Journal of Cancer 122 (12) , pp. 2744-2752. 10.1002/ijc.23467 |
|
|
Cardiff University Information Services